Neogenomics (NEO) Other Operating Expenses (2011 - 2026)

Neogenomics (NEO) has 16 years of Other Operating Expenses data on file, last reported at $10.8 million in Q2 2026.

• Quarterly Other Operating Expenses fell 62.97% year-over-year to $10.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $45.9 million (down 16.43% YoY) and the FY2025 annual result came in at $64.8 million, up 108.06% from the prior year.
• Other Operating Expenses climbed to $10.8 million in Q2 2026, from $9.5 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $29.1 million in Q2 2025 to a low of $5.3 million in Q3 2023.
• A 5-year average of $9.7 million and a median of $7.8 million in 2022 frame the typical range for Other Operating Expenses.
• Annual changes were most pronounced in 2025 — Other Operating Expenses soared 268.55% — and 2026, when it tumbled 62.97%.
• Tracing NEO's Other Operating Expenses over 5 years: stood at $6.7 million in 2022, then increased by 6.77% to $7.1 million in 2023, then grew by 11.81% to $8.0 million in 2024, then increased by 23.04% to $9.8 million in 2025, then climbed by 9.75% to $10.8 million in 2026.
• The last three Other Operating Expenses figures came in at $10.8 million (Q2 2026), $9.5 million (Q1 2026), and $9.8 million (Q4 2025), per Business Quant data.